Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial

Stone J, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Roche Products Limited and Roche Diagnostics Limited

United Kingdom (GB) Hospital for Special Surgery (HSS)

United States (USA) (US) University of Groningen / Rijksuniversiteit Groningen

Netherlands (NL) Universitat de Barcelona (UB) / University of Barcelona

Spain (ES) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

Belgium (BE) Harvard University

United States (USA) (US) Arcispedale Santa Maria Nuova

Italy (IT) Southend Hospital

United Kingdom (GB) Technische Universität Dresden

Germany (DE) Genentech Inc.

United States (USA) (US)

How to cite

APA:

Stone, J., Spotswood, H., Unizony, S., Aringer, M., Blockmans, D., Brouwer, E.,... Bao, M. (2019). Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.

MLA:

Stone, John, et al. "Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2019.

BibTeX: Download